12 HR Oxymorphone Hydrochloride 30 MG Extended Release Oral Tablet

1 INDICATIONS AND USAGE Oxymorphone hydrochloride extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Oxymorphone hydrochloride extended-release tablets are an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve oxymorphone hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Oxymorphone hydrochloride extended-release tablets are not indicated as an as-needed (prn) analgesic. ( 1 ) Limitations of Usage Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions (5.1) ] , reserve oxymorphone hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Oxymorphone hydrochloride extended-release tablets are not indicated as an as-needed (prn) analgesic.

Amneal Pharmaceuticals LLC

FDA Reported Adverse Reactions
`[1] fatigue` `[2] nausea` `[3] dyspnoea` `[4] diarrhoea` `[5] dizziness` `[6] drug ineffective` `[7] headache` `[8] pain` `[9] asthenia` `[10] fall`

4 years ago

ROUND BROWN G77

16 HOW SUPPLIED/STORAGE AND HANDLING

OXYMORPHONE HYDROCHLORIDE extended-release tablets, USP are supplied as the following strengths:

OXYMORPHONE HYDROCHLORIDE Extended-Release Tablets USP, 5 mg are purple, round, film-coated extended-release tablets debossed with “G71” on one side and blank on the other side. They are available as follows: Bottles of 30: NDC 64896-695-08 Bottles of 60: NDC 64896-695-13 Bottles of 100: NDC 64896-695-01 Bottles of 1000: NDC 64896-695-03

OXYMORPHONE HYDROCHLORIDE Extended-Release Tablets USP, 7.5 mg are gray, round, film-coated extended-release tablets debossed with “G75” on one side and blank on the other side. They are available as follows: Bottles of 30: NDC 64896-696-08 Bottles of 60: NDC 64896-696-13 Bottles of 100: NDC 64896-696-01 Bottles of 1000: NDC 64896-696-03

OXYMORPHONE HYDROCHLORIDE Extended-Release Tablets USP, 10 mg are orange, round, film-coated extended-release tablets debossed with “G72” on one side and blank on the other side. They are available as follows: Bottles of 30: NDC 64896-697-08 Bottles of 60: NDC 64896-697-13 Bottles of 100: NDC 64896-697-01 Bottles of 1000: NDC 64896-697-03

OXYMORPHONE HYDROCHLORIDE Extended-Release Tablets USP, 15 mg are white, round, film-coated extended-release tablets debossed with “G76” on one side and blank on the other side. They are available as follows: Bottles of 30: NDC 64896-698-08 Bottles of 60: NDC 64896-698-13 Bottles of 100: NDC 64896-698-01 Bottles of 1000: NDC 64896-698-03

OXYMORPHONE HYDROCHLORIDE Extended-Release Tablets USP, 20 mg are green, round, film-coated extended-release tablets debossed with “G73” on one side and blank on the other side. They are available as follows: Bottles of 30: NDC 64896-699-08 Bottles of 60: NDC 64896-699-13 Bottles of 100: NDC 64896-699-01 Bottles of 1000: NDC 64896-699-03

OXYMORPHONE HYDROCHLORIDE Extended-Release Tablets USP, 30 mg are brown, round, film-coated extended-release tablets debossed with “G77” on one side and blank on the other side. They are available as follows: Bottles of 30: NDC 64896-700-08 Bottles of 60: NDC 64896-700-13 Bottles of 100: NDC 64896-700-01 Bottles of 1000: NDC 64896-700-03

OXYMORPHONE HYDROCHLORIDE Extended-Release Tablets USP, 40 mg are orange, round, film-coated extended-release tablets debossed with “G74” on one side and blank on the other side. They are available as follows: Bottles of 30: NDC 64896-701-08 Bottles of 60: NDC 64896-701-13 Bottles of 100: NDC 64896-701-01 Bottles of 1000: NDC 64896-701-03 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in tight container as defined in the USP, with a child-resistant closure (as required). Store

OXYMORPHONE HYDROCHLORIDE extended-release tablets securely and dispose of properly [see Patient Counseling Information (17) ] .

More pills like ROUND G77

Related Pills

oxymorphone hydrochloride 20 mg tablet film coated extended release

amneal pharmaceuticals llc

12 HR Oxymorphone Hydrochloride 15 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

12 HR Oxymorphone Hydrochloride 10 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

12 HR Oxymorphone Hydrochloride 5 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

12 HR Oxymorphone Hydrochloride 40 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

12 HR Oxymorphone Hydrochloride 7.5 MG Extended Release Oral Tablet

Amneal Pharmaceuticals LLC

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site